Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey
mCRPC is a life-changing diagnosis with physical, psychological, and financial burdens. By encouraging early genetic testing and fostering patient-centered conversation, HCPs can provide personalized care for optimized treatment outcomes in mCRPC.
Authors
- Jutta Weiser
- Emma Smith (ORCID: https://orcid.org/0000-0003-2541-5723)
- Matthew J. Pagano (ORCID: https://orcid.org/0000-0002-5769-1776)
- Neerav Monga (ORCID: https://orcid.org/0000-0003-4693-7256)
- Katie Pascoe (ORCID: https://orcid.org/0000-0001-5742-4654)
- Katherine B. Bevans (ORCID: https://orcid.org/0000-0003-0145-7945)
- Ruhee Jain
- Andrea Stevens
- Rob Seebold
Institutions
- Johnson & Johnson (United States) (US)
- Johnson & Johnson (Israel) (IL)
- Johnson & Johnson (United Kingdom) (GB)
- Enzo Biochem (United States) (US)
- Bühler (United Kingdom) (GB)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1080/14796694.2025.2510890
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Johnson and Johnson